Table 3.
Oligometastatic disease in NPC and HPV+ tumors
| Study | Design | Patients | Treatment | Results |
|---|---|---|---|---|
|
| ||||
| Huang et al36 | Retrospective | 79 oropharynx, HPV+ 54 vs HPV− 25 | CRT of primary tumor | 2-year OS 11% in HPV+ vs 4% in HPV− |
| McBride et al37 | Retrospective | 25 oropharynx 84% primary controlled, 95% HPV+ | Surgery or RT on metastases | Limited DM and KPS >80 2-year OS 100% |
| Sinha et al35 | Retrospective | 66 oropharynx, 62% HPV+ | Curative approach in 12% HPV+ and 27% HPV− | 2-year PFS 20% in HPV+ vs 0 in HPV+ |
| Shen et al39 | Retrospective | 312 NPC, bone only | CRT vs palliative | 5-year OS 57.3% in CRT vs 11.2% in palliative treatment |
| Cao et al40 | Retrospective | 221 NPC, single | CRT, CT | 5-year OS 49.5 vs 19.4, low- and high-risk subsets |
Abbreviations: CT, chemotherapy; CRT, chemoradiotherapy; DM, distant metastasis; HPV, human papillomavirus; NPC, nasopharyngeal cancer; OS, overall survival; PFS, progression-free survival.